Stomach ultrasound study for diabetes and obesity
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study uses ultrasound to see how GLP-1 RA medications (like Ozempic) affect the stomach in people with type 2 diabetes and obesity. It may help doctors better understand how these medicines work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a body mass index (BMI) over 35.
- You have type 2 diabetes.
- You are either currently taking a GLP-1 RA medication (like Ozempic or Wegovy) or you are not taking one.
- You do not have a condition called gastroparesis (slow stomach emptying).
- You have not had gastric bypass or any other stomach surgery.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what happens when people taking a GLP-1 medication (like Ozempic) either stop or continue it after weight loss surgery. The goal is to learn whether staying on the medicine helps with long-term weight control.
This study will look at how medicines like Ozempic, Wegovy, and Mounjaro affect how well the stomach and intestines move food through the body. It might help find out why these medicines cause digestive problems for some people.
This study tests if a type 2 diabetes medication called a GLP-1 receptor agonist (like Ozempic) is safe and effective for people on dialysis. It may help manage blood sugar and improve health outcomes for those with kidney failure.
This trial uses a stomach ultrasound (called gastric POCUS) to check if your stomach is empty before surgery. It is for patients taking GLP-1 medications (like Ozempic, Wegovy, or similar) to help make sure it is safe to proceed with anesthesia.
This study uses an ultrasound to look at how full your stomach is after taking GLP-1 medications for diabetes or weight loss. It will help doctors understand if current fasting guidelines are safe before surgery or a colonoscopy.
This study looks at how a newly started GLP-1 medicine (commonly used for weight loss or diabetes) changes the amount of food left in your stomach and how fast it empties. The goal is to understand these effects better, which may help improve safety and dosing.
Hear when a new Delayed Gastric Emptying trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.